BCDA COLLEGE OF PHARMACY & TECHNOLOGY

Hridaypur, Barasat, Kolkata-700127

UNIT-I: Multiple Choice Questions (MCQs)

Subject: B. Pharm Course: Novel drug Delivery Systems Code: PT-716B

Year: 4th Semester: 7th Session: 2020-21(Odd)

1. Rate determining step for controlled release delivery system is

a) Absorption b) Drug release from dosage form c) Both d) None

Ans: b

2. By controlled release drug delivery systems bioavailability is

a) improved b) decreases c) both d) none

Ans: a

3. Following is continuous release system

a) mucoadhesive systems b) colon targeted systems

c)dissolution control release system d)intestinal release system

Ans: c

4. The example of natural polymer is

a) Gun cotton b) cellulose acetate c) Buna R d) Albumin.

Ans: d

5. More than 95 % drugs are absorbed by this mechanism.

a. Dissolution b. Diffusion c. passive diffusion d. direct absorption

Ans: c

6. The biological factor influencing the design and act of controlled release product is

a) Partition coefficient b) Absorption c) Molecular size d) Solubility

Ans: b
7. Drugs with ---------therapeutic index are unsuitable for incorporation in controlled release
formulation

a. High b. low c. Moderate d. None of this

Ans .b

8. Products designed to release their medication in a controlled manner at a predetermined

rate, duration and location to achieve and maintain therapeutic blood levels of drug

a. Immediate Release b. Extended Release c. Targeted Release d. None of the above

Ans: b

9. Zero order release kinetics is attained in

a.sustain release b.controlled release c.Enteric coating d.Immediate coating

Ans: b

10. The abbreviation used for extended release is

a. ER b. XL c. XR d. All of the above

Ans: d

11. Following is delayed release system

a. Diffusion controlled release system b. colon targeted system c. Dissolution controlled

release system d. Hydrodynamic controlled release system

Ans: b

12. Diffusion controlled Modified Release (MR) system consist of

a. Hydrophobic matrix systems b. Hydrophobic reservior systems c. Hydrophillic matrix systems

d. Both a&b

Ans: d

13. The duration of action of parental controlled release systems can be extended up to what
time?

a) 1 day b) 1 week c) 1 month d) Day, week, month even a year

Ans: d
14. Drug having molecular weight ------------------ is good candidate for controlled release
dosage form

a) More than 2000 dalton b) Less than 600 dalton c) Over and above 1000 dalton

d) None of the above

Ans: b

15. What does the polymer coating of diffusion controlled release tablet do for its release

a) Binds with the drug

b) Has low solubility low permeability and ph independent swelling which allows diffusion of the
drug (water diffuses in and drug diffuses out)

c) Erosion of the surface d) All the above

Ans: b

16. The absorption of the ophthalmic drug does not depend on which of the following?

a) Physicochemical properties of the permeating molecule

b) Drainage of tears c) Output of tears d) Size of the eyeball

Ans: d

17. The drugs that cannot be administered transdermally are

a) Drugs with very short half-lives b) Drugs with narrow therapeutic indices

c) Easy removal and termination d) Drugs against peptic ulcer

Ans: d

18. Mechanism of controlled drug delivery include

a) Osmosis controlled b) bio responsive controlled release c) dissolution controlled

d) all of the above

Ans: d

19. Release of water-soluble drugs can be retarded by presenting it as ____________

suspension.

a) Oil b) Water c) Colloidal d) Freezing

Ans: a

20. Polymers are used in various drug delivery systems to

a) Modify Pharmacokinetic Profile b) Modify Pharmacodynamics Profile

c) For Drug Targeting d) All of the above

Ans: d

21. It is the fraction of drug in an oil phase to that of an aqueous phase

a. pKa b. Permeation c. Dissolution d. Partition coefficient

Ans : d

22. One of the following polymer type is not classified on the basis of its application &
properties

a. Rubber b. Polymer c. Fiber d. Synthetic

Ans: d

23. Ideally, the drug should have half-life to be formulated in controlled release dosage

a. 3-4hrs b. 1-2 hrs c. 6-7 hrs d. 9-10 hrs

Ans: a

24. Floating drug delivery dosage forms are prepared by using following polymer

(a) Gelatin (b) HPMC (c) EC-Ethyl cellulose (d) MC-Methyl cellulose

Ans: b

25. Select the type of drug that can be incorporated in liposomes

a.Lipophilic b.Hydrophilic c. Both d.None

Ans: c

26. Release kinetics from dissolution control system is governed by

a. Fick's law of diffusion b. Noyes Whitney equation c. Zero order d, First order

Ans: b

27. Major drawback of parental controlled release systems

 a) Injecting is a difficulty b) The drug cannot be easily removed once administered

c) Can get easily precipitated in the injection site d) Rapid onset but fast excretion

Ans: b

28. Example of inert plastic materials used for plastic matrix is

a. Polyethylene b. Polyvinyl acetate c. Polymethacrylate d. All of the above

Ans: d

29. Example of hydrophilic erodible polymers is

a. Methyl cellulose b. Hydroxyethylcellulose c. Sodium alginate d. All of the above

Ans: d

30. Glyceryl trinitrate is given through sublingual route because of

a. short plasma half life b. hepatic first pass metabolism avoidance

c. protein binding d. lower bio availability by oral route

Ans: b

31. The drugs of delayed release systems are those that are

a. absorbed from a specific intestinal site b. meant to exert local effect at a specific GI site

c. Only a d. Both a & b

Ans: d

32. Advantage of controlled release dosage form

a. Patient Compliance b. Reduction in the frequency of designing

c. Improved efficacy in treatment. d. All of the above.

Ans: d

33. All are the disadvantages of control drug delivery except

a) poor patient compliance b) need of additional patient education

c) poor in vivo, in vitro Co relation d) dose dumping

Ans-: a
34. Find one of the following which should not be a characteristic of the vehicles or polymers
which are used for parenteral formulations

a) Sterile b) Consists of pyrogen c) Nonirritating d) Biodegradable

Ans: b

35. ------- is the characteristics of diffusion- controlled release system

a. Release the drug along the entire length of GIT b. Diffusion of the dissolved drug
c. Release only at a specific drug d. Employ waxes to control the rate of dissolution
Ans:-b

36. Dosage form that have drug release features based on time course and location which are
designed to accomplish therapeutic objective not offered by conventional are:
a. Immediate release b. Modified release c. Diffusion mediated release d. All the above
Ans:-b
37. Ion activated DDS is ----------- type of activated systems

a. Physical b. Chemical c. Biochemical d. All of the above

Ans:-b
38. Among the following all are colloidal controlled drug delivery system except
a. Microsphere b. Nanoparticles c. Liposomes d. Transdermal patches
Ans:-d

39. For a drug to be formulated in to controlled/modified release dosage form it’s Margin of
safety should be----
a. Very low b. Very high c. Normal d. None of above
Ans:-b
40. Immediate release drug delivery system lacks which of the following characteristics

a. Dose maintenance b. Controlled release rate c. Site targeting d. All of above

Ans:-d
41. Liposomes are:
a. Type of enzymes b. Fibrinopeptides c. Red blood cells d. Unit or multilayered vesicles of
phospholipids
Ans: d
42. Control release drug delivery system works
a. Locally b. Systemically c. None of the above d. Both a & b

Ans:-d
43. Dissolution of drugs depend upon
a. Thickness of diffusion layer b. Surface area of the exposed solid
c. Saturated solubility of the drug d. All of the above
Ans:-d
44. Controlled drug delivery system provides the concentration of drug to the absorption site

a. Uniform b. Consistent c. Reliable d. Same

Ans: a

45. Product designed to release their medication in a controlled manner at a predetermined

rate, duration and location to achieve and maintain therapeutic blood levels of drug

a. Immediate release b. Extended release c. Targeted release d. None of the above

Ans: b

46. A lipid bilayer structure that encloses an internal aqueous volume is

a) Niosome b) Liposome c) Solid lipid nanoparticle d) Nanoparticle

Ans: b

47. The polymer used in " Lacriset " is

a- hydoxy ethyl cellulose b- hydoxy methyl cellulose c- methyl cellulose d- hydroxy propyl
cellulose

Ans: a

48. Matrix Systems are also known as

a) Reservior system b) Monolithic system c) Microcapsule d) all of the above

Ans: b
 BCDA COLLEGE OF PHARMACY &TECHNOLOGY
Hridaypur, Barasat, Kolkata -700127

UNIT-II: Multiple Choice Questions (MCQs)

Subject: B. Pharm Course: Novel Drug delivery Systems Code: PT - 716B

Year: 4th Sem: 7th Session: 2020 – 2021 (odd)

1. The advantage of Microencapsulation is

a. Sustained release of prolonged action medications

b. Taste masked chewable tablet, powders and suspensions

c. Single layer tablet for chemically incompatible ingredients

d. All of the above

Ans: d

2. Nano sized particles of supramagnetic iron oxides used in

a. Bioadhesive microsphere b. Magnetic microsphere

c. Radioactive microsphere d. Floating microsphere.

Ans: b

3. Advantages of mucosal drug delivery system include

a. excellent accessibility b. painless administration

c. prolongation of residence time d. all of the above

Ans: d

4. Following is the technique used for coacervation micro encapsulation technique

a. change in temperature b. incompatible polymer addiction

c. non solvent Addiction d. all of the above

Ans: d

5. Mucosal drug delivery system associated with the gum is termed as

a. sublingual delivery b. buccal delivery c. gingival delivery d. nasal delivery

Ans: c

6. The proportion of free proteins present in mucosa is

a. 0.5-5%. b.10% c. 0.5-1%. d. 0.1-0.5%

Ans: c

7. The Oral cavity has been used as a site for ___________drug delivery.

a. local b. systemic c. both. d. none of them

Ans: c

8. Removal of which type of implant are necessary after completion of therapy

a. Biodegradable implant b. Non biodegradable implant c. Both d. None

Ans: b

9. Factors affecting Mucoadhesion are:

a. Flexibility of polymer chains b. Presence of functional group

c. pH of polymer substrate interface & Mucinturn over d. All

Ans: d

10. Solvent evaporation is which type of micro encapsulation technique?

a. chemical b. physical c. physico chemical d. all of the above

Ans: a

11. The implant which has no moving part

a. active implant b. passive implant c. both d. none

Ans: b

12. In microencapsulation, Wurster process is used in

a. Coacervation phase separation b. Air suspension

c. Multi orifice centrifugal process d. polymerization

Ans: b
13. An ideal MDDS formulation consist of

a) Mucoadhesive agent b) penetration enhencer c) Enzyme inhibitor d)All

Ans: d

14. Example of Hydrolysis Activated Drug delivery system is

a) Infusaid b) Norgastomet releaseing HYDRON implants

b) c) Lupron d) Glucose Triggered insulin delivery system

Ans: c

15. Drugs that get mostly absorbed from the mouth

a) Acidic drugs and lipophilic drug b) Lipophilic drugs and neutral drugs

c) Neutral drugs and lipophilic drugs d) Lipophilic ,neutral and basic drugs
Ans: a

16. Using encapsulation data security is

a) Not ensured b) Ensure to some extent c) Purely ensured d) Very low

Ans: b

17. Permeation enhancer used in mucosal drug delivery system

a) Methyl paraben b) Calcium chloride c) Sodium taurocholate d) Sodium chloride

Ans: c

18. Water insoluble Mucoadhesive polymer is

a) Carbopol b) PEG c) Both a & b d) PVP

Ans: c

19. Following is a characteristic of microspheres

a) Free flowing powders b) Aqueous solutions

c) Control drug release by partitioning the drug from the oil d) Administration of emulsions
Ans: a

20. Physiological factors that affect mucoadhesion

a) Molecular weight b) Mucin Turnover c) pH d) Contact Time

Ans: b

21. Evaluation test of Mucoadhesive Drug Delivery systems of Tablets is

 a) Weight variation b) Hardness c) both a &b d) none of above
Ans: c

22. The maximum capsule size & shape for convenient oral use in human is

a) 20 minim oblong b) 16 minim oval c) 9 minim round d) all the above

Ans: d

23. Encapsulation of drug formulation in to the reservoir compartment can be done by

a) Injection molding b)Spray coating C)Microencapsulation d) All of the above

Ans: d

24. Main Characteristics of mucoadhesive systems is

a) Release the drug along the entire length of GIT b) Prolonged their residence in the GIT &
release c) Usage of bioadhesive polymer d) Use of high or low density pellets.

Ans: c

25. Coating solidification in ............. is solidifying a dissolved coating by introducing the

coating core material mixture into non - solvent

a) spray drying b) spray congealing c) both a & b d) none of the above

Ans: b

26. Device containing pilocarpine and alginic acid in a drug reservoir is used in

a) Tuberculosis Therapy b) Ocular Therapy c) Diabetes Therapy d) Dental Therapy

Ans: b

27. Chitosan is____ type of polymer

a) anionic b) cationic c) neutral d)non of above

Ans: b

28. Tablets that are placed under the skin are

a) Enteric - coated tablets b) Flim-coated tablets c) Implants d) Sublingual tablets

Ans: c

29. Following is the physical method of microencapsulation technique

a. Polymerisation b. Solvent evaporation c. Air suspension d. All of the above

Ans: c

30. So many difficulties are observed during microencapsulations process. The incorrect
answer is

a) Incomplete or discontinuous coating b) Inadequate stability

c) Non-reproducible and unstable release characteristic d) Economic

Ans: d

31. The layer described as translucent and viscid secretion which forms a thin continuous
gel blanket adherent to the mucosal epithelial surface

a. Mucous layer b. Epithelium c. Basal lamina d. Connective tissue

Ans: a

32. Following are the theories of "Mucoadhesion", except

a. Wetting theory b. Absorption theory c. Fracture theory d. Diffusion theory

Ans: b

33. Micron or submicron particles can be effectively encapsulated by _______ techniques.

a) Air suspension b) centrifugal extrusion c) Pan coating d) vibrational nozzle

Ans: a

34. Water insoluble resin used as coating material for microcapsules is

a) Starch b) polyethylene c) gelatin d) PVP

Ans: b

35. Stearic acid is a coating material of the following category

a) Water insoluble resin b)Water soluble resin c)Wax and lipid d)Enteric coating resin

Ans: c

36. Pharmaceutical application of microencapsulation technique is

a) prolonged release b) Reduce gastric irritation c)Taste masking d)None of the above

Ans: d
37. Following can be considered as physico-mechanical technique used for
microencapsulation

a) Phase Inversion b) Coacervation c) Co-extrusion d) Hot Melt

Ans: c

38. Following is complex coacervation method

a) Change in temperature b) incomplete polymer addition

c) non solvent addition d)polymer polymer interactions

Ans: d

39. A water soluble substance is used as coating material in microencapsulation process is

a) polyethylene b) silicone c) hydroxyethyl cellulose d) paraffin

Ans: c

40. The fundamental consideration for the formulation of microcapsules includes

a) core materials b) coating materials c) vehicle d) All of the above

Ans: d

41. Shellac is the coating materials for microcapsules of following category

a. water soluble resin b. water insoluble resin c. enteric coated resin d.wax resin

Ans: c

42. Coacervation is _ type of microencapsulation technique

a. physical b. chemical c. physicochemical d. All of the above

Ans: c

43. Microencapsulation depends on the following

a. melting point of the material b. relatively of the material

c. chemical properties of the material d. sensitivity of the material

Ans: c

44. Advantages of microencapsulation includes all except

a. Sensory properties remain unaltered b. Shelf life may be increased

c. Shelf life of hygroscopic drugs is reduced d. Both a & c

Ans : c

45. Solvent evaporation microencapsulation technique applicable for core material

a) solid & liquid b) solid c) liquid d) volatile liquid

Ans: a

46. Following is the characteristic of the mucoadhesive system

a. Release the drug along the entire length of GIT b. Prolonged their residence in the GIT

c. Usage of bio adhesive polymer d. Use of high or low density plate

Ans: c

47. Goblet cells or salivary glands secretes ------- directly onto the epithelial surfaces

a) water b) mucus c) oil d) none

Ans: b

48. Following is the functionality of 'encapsulation'

a. Bind together code of action b. Using single interface for general class of actions.

c. Reduce complexity d. All of the mentioned

Ans: a

49. Factors affecting Mucoadhesion are:

a) Flexibility of polymer chains b) Presence of functional group

c) pH of polymer substrate interface & Mucinturn over d) All

Ans: d

50. Advantages of microencapsulation includes all except

a. Sensory properties remain unaltered b. Shelf life may be increased

c. Shelf life of hygroscopic drugs is reduced d. Both a & c

Ans : c
51. Drug release rate from microcapsules conforming to reservoir type is

a) first order b) slow first order c) zero order d) none of the above

Ans : c

52. Followings are major components of all mucous gel except

a. glycoprotein b. lipids c. water d. amino acid

Ans: d

53. Followings are mucosal drug delivery systems except

a. buccal delivery systems b. ocular delivery systems

c. parenteral delivery systems d. oral delivery systems

Ans: c

54. Physiological factor that can affect mucoadhesion is

a. Molecular weight b. Mucin turnover c. pH d. Contact time

Ans: b

55. The limitation of implantable DDS is

(a) Limited to potent Drugs (b) Possibility of adverse reaction

(c) Biocompatibility issue (d) All of the above

Ans: d

56. Oral mucosal drug delivery system is divided in two parts

a) Buccal and nasal b) Buccal and In muscular c) Sublingual and nasal d) Buccal and sublingual

Ans: d
 BCDA COLLEGE OF PHARMACY &TECHNOLOGY
Hridaypur, Barasat, Kolkata -700127

UNIT-III: Multiple Choice Questions (MCQs)

Subject: B. Pharm Course: Novel Drug delivery Systems Code: PT - 716B

Year: 4th Sem: 7th Session: 2020 – 2021 (odd)

1. The approach used in Transdermal drug delivery system is

a. Sonophoresis b. Electrophoresis c. Both a and b d. None of the above

Ans: c

2. __ is the most noticeable disadvantages of gastroretentive floating drug delivery systems.

a. Requirement of high level of fluid b. Delay release

c. Absorption of acid soluble drug d. Vigorous intestinal movement

Ans: a

3. First transdermal patch approved in 1979 was for the following drug

a. pain(fentanyl) b. Motion sickness(scopolamine)

c. smoking cessation(nicotine) d. pain (lidocaine)

Ans: b

4. Physicochemical factor effecting TDDS

a. Sun light b. Partition coefficient c. Air pollution d. Cold season

Ans: b

5. Drug eluting stents are the best example of TDDSs for

a. Vascular disease treatment b. Pain management c. Diabetes d. All of the above

Ans: a

6. The rate at which monolithic devices transfer drugs to the patient body is proportional to
____of time.
a. Square of time b. The square root of time c. Twice the time d. Half the time

Ans: b

7. The characteristic that is suitable for transdermal drug is

a. Large drug dose b. large molecular size

c. Drugs with narrow therapeutic index d. Drugs which are metabolized in the skin

Ans: c

8. The approaches that can be included in formulation of nasopulmonary drug delivery

systems is/are

a. liposome b. Microspheres c. nasal powder d. all of the above

Ans: d

9. The primary barrier to Transdermal drug delivery is-

a. Dermis b. Epidermis(stratum corneum) c. Hypodermis d. all of the above

Ans: b

10. Preservative used in the Nasal spray is

a) Paraben b) PEG c) Glycerine d)Acetone

Ans: a

11. Intranasal administration is an attractive route for _______action

a. local b. Systemic c. none d. both

Ans: d

12. Not applicable for evaluation of TDDS

a) Quick stick test b) probe tack test c) skim peel test d) thumb tack test

Ans:c

13. Test apparatus used to study drug release form TDDS

a) Paddle over disc b) Rotating cylinder c) Basket apparatus d) Both a &b

Ans: d
14. Silicone, Polybutyl acrylate, polyisobutylene are examples of

a) Backing membrane b) Polymer matrix c) Permeation enhancers d) Adhesives

Ans: d

15. Well developed “intercellular lipid lamellae” is a feature of which layer of the
epithelium.

a) Stratum basale b) Stratum spinosum c) Stratum lucidum d) Stratum corneum

Ans: d

16. Disadvantage of TDDS is

a) Self-administration b) molecular size >500

c) low drug level in blood/plasma d) none of them.

Ans: c

17. The mechanism of chemical permeation enhancer is

a)Cause deposition of penetrant in the stratum corneum

b)Alter physicochemical properties of stratum corneum

c)Causes reversible damage to the stratum corneum d)Both b & c

Ans: d

18. Iontophoresis is used in TDDS as

a) Physical penetration enhancer b)Chemical penetration enhancer

c)Drug carrier d)Polymer matrix

Ans: a

19. --------------- cannot be given as transdermal administration

a) Drugs with very short half-lives b) Drugs with narrow therapeutic indices

c) Easy removal and termination d) Drugs against peptic ulcer

Ans: d

20. Components of trandermal drug delivery system is/ are

a. Drug substance b. Polymer matrix c. Backing membrane d. All of the above

Ans: d

21. Transdermal nicotine patch is used worldwide for -

a. Hypertension b. Smoking cessation therapy c. Diabetes d. Anti-inflammatory

Ans: b

22. Stratum corneum, an outermost layer of skin is also called as

a. Corneocytes b. Horny layer c. Hypodermis d. Dermis

Ans: b

23. In TDDS silicone, polyacrylate act as

a. Adhesive b. Backing membrane c. Release liner d. None

Ans: a

24. Most of the drugs get absorbed through the skin by the following mechanism

a. active transport b. passive transport c. facilitated transport d. osmosis

Ans: b

25. Transdermal drug delivery system is related to

a. Dosage forms applied to intact skin b. Dosage form administered systemically

c. Dosage form administered in colon d. None

Ans: a

26. Floating microspheres are gasto retentive drug delivery systems based on ______
approach

a) effervescent b) non- effervescent c) Both a & b both d) none of these

Ans: b

27. One of the following is used as a spraying reagent in paper chromatography

a. Conc. HCL acid b. NaCl solution c. Ninhydrin solution d.CuSO4 solution

Ans: c
28. Bile salts like sodium deoxycholate, sodium glycocholate are used in nasal drug delivery
system as

a. Absorption enhancers b. Bioadhesive c. Propellant d. Anti-allergics

Ans: a

29. Following is the rate controlling barrier evaluated for transdermal application

a. Poly-2 hydroxyethylmethacrylate b. Poly-2 hydroxypropionic acid

c. Poly-2 hydroxypropyl dimethyl ammonium chloride d. Both b and c

Ans: a

30. Role of chemical enhancer in transdermal drug delivery system is

a. To increase skin permeability b. to decrease skin permeability c. Both a & b d. None.

Ans: a

31. Hollow microspheres are a non effervescent approach for GRDDS are also known as

a) Microballs b) Microballoons c) Floating Beads d) Alginate beads

Ans: b

32. Thickness of alveolar region in Nasopulmonary Drug Delivery System is

a) 0.1-0.5 micrometer b) 0.25-1.25 micrometer c) 1.25-2.25 micrometer d) 0.5-1.5 micrometer

Ans: a

33. Followings are the materials commonly used for bioadhesion except

a) Chitosan b) Sodium bicarbonate c) Tragacanth d) Sodium alginate

Ans: b

34. The aerosol medication particles must be of _____ size for inhalation and deposition in
the airway.

a) 0.5-4.5μm b) 7. 5-12 μm c) Both a & b d) 15.5- 18.5 μm

Ans: a

35. The mechanism by which of the peptide is absorbed in nasal cavity is

a) Tanscytoic. b) paracellular (intracellular) c) transcellular d) none of the above

Ans: b

36. Drugs used in ‘Nesal spray’ is/are

a) Beclomethasone b) Oxymetazoline c) Both a & b d) None of these

Ans: c

37. The ideal molecular weight for the drug for Transdermal drug delivery system is_____

a) Not more than 800 Dalton b) Not more than 1000 Dalton

c) Not more than 400 Dalton d) Not more than 1200 Dalton

Ans: c

38. Physicochemical factor affecting TDDS is

a) Sun light b) Partition coefficient c) Cold season d) Air pollution

Ans: b

39. In nasopulmonary drug delivery system the absorption can be enhanced by which of
the following approaches

a) Use of absorption enhancers b) Increase in residence time

c) Use of physiological modifying agents d) All of the above

Ans: a

40. Normal pH of the nasal secretion in adult is

a) 5.5-6.5 b) 3.5-4.5 c) 6.5-7.5 d) 2.5-3.5

Ans: a

41. Suitable candidate for GRDDS include all, except

a. Levodopa b. Ranitidine HCl c. Phenytoin d. Riboflavin

Ans: c

42. Hollow microspheres are a non effervescent approach for GRDDS are also known as

a. Microballs b. Microballoons c. Floating Beads d. Alginate beads

Ans: b
43. Following drugs cannot be given as transdermal administration

a) Drugs with very short half-lives b) Drugs with narrow therapeutic indices

c) Easy removal and termination d) Drugs against peptic ulcer

Ans : d

44. Transdermal drug delivery system is related to

a) Dosage forms applied to the skin b) Dosage forms administered systemically

c) Dosage forms administered in colon d) None

Ans: a

45. From the following anatomical structure the drugs from TDDS enter the systemic
circulation

a. Epidermis b. Dermis c. Sweat glands d. Hypodermis

Ans: b

46. To increase the GRT, following approach is not applicable

a. High density system b. Floating system c. Compressible system d. Bioadhesive system

Ans: c

47. Targeted drug delivery system is also referred as

a. Passive targeting b. Active targeting c. Second order targeting d. Smart drug delivery system

Ans. d

48. The characteristic of the monolithic devices is

a) The drug has a large therapeutic index b) Aqueous solutions

c) Control drug release by partitioning the drug from the oil d) Administration of emulsions

Ans: a

49. Mechanism involved in nasal absorption enhancement is

a) decreased molecular weight b) decreased paracellular transport

c) increased enzymatic degradation d) increased Transcellular transport

Ans: d

50. Migrating mayoelectric complex (MMC) is

a) mobility pattern of stomach b)gastric emptying c) mixing of food d) all of the above

Ans: a

51. Drug eluting stents are the best example of TDDSs for

a. Vascular disease treatment b. Pain management c. Diabetes d. All of the above

Ans: a

52. Backing membrane, Control membrane, Matrix polymer, Adhesive layers are
components of

a. Osmotic pumps b. Transdermal patches c. Liposomes d. Resealed erythrocytes

Ans: b

53. In Nasopulmonary drug delivery systems the absorption can be enhanced by following
approaches

(a) Use of absorption enhancer (b) Increases in residence time

(c) Use of physiological modifying agents (d) All of the above

Ans: d

54. Iontophoresis is used in TDDS as a

a. Physical penetration enhancer b. Polymer matrix c. Drug Carrier d. Both a and b

Ans: a

55. Laurocapram & Lemon oil are used in TDDS as

a) Adhesive b) Drug carrier c) Penetration enhancer d) polymer matrix

Ans: c

56. Disadvantages of drug powder inhaler is

a) DPIs are small devices b) Liberation of powders from the device and segregation of particles

c) DPIs are portable devices d) None of the above

Ans: b
 BCDA COLLEGE OF PHARMACY &TECHNOLOGY
Hridaypur, Barasat, Kolkata -700127

UNIT-IV: Multiple Choice Questions (MCQs)

Subject: B. Pharm Course: Novel Drug delivery Systems Code: PT - 716B

Year: 4th Sem: 7th Session: 2020 – 2021 (odd)

1. Passive targeting is based on

a. Enhanced permeability b. Retention c. Mechanical disruption d. All of the above

Ans: d

2. In nanoparticles the particle size / size distribution may be studied by

a. PCS b.SEM c.TEM d. All of the above

Ans: d

3. Targeting drugs to specific organ is called

a. spatial placement b. temporal delivery c. both d. none of the above

Ans: a

4. Ideal characteristics of targeted drug delivery system

a. Nontoxic and biodegradable b. Biocompatible and physicochemically stable

c. Predictable and controllable rate of drug release d. All of the above

Ans: d

5. The following characharictics is/are true for niosomes

a. Biocompatible b. Non immunogenic c. Biodegradable d. All of the above

Ans: d

6. In physical targeting following characteristic is changed

a. Temperaturee b. Light intensity c. Electric field d. All of the above

Ans: d
7. In nanoparticle technology, LDC stands for

a. Liquid drug concentration b. Lyophilic drug conjugates

c. Lyophobic drug conjugates d. Lipid drug conjugates

Ans: d

8. Niosomes are formulated by using ________ surface active agents

a. cationic b. non-ionic c. Anionic d. zwitter-ionic

Ans: b

9. Size ranges for liposomes is

a) 25 to 5000 nm b) 1 - 100 nm c) 10 to 100 nm d) >5000 nm

Ans: a

10. Advantages of solid lipid nanoparticles includes

a. Easy to scale-up and sterilize b. Water based technology

c. More affordable d. All of the above

Ans: d

11. Diameter of OLV is

a) 50 nm b)100-1000nm c)more than 1000nm d)less than 100nm

Ans: b

12. Major components of niosomes preparation

a) Cholesterol b) non-ionic surfactants c) both a & b d) ionic surfactants
Ans: c
13. Advantages of niosomes
a) They are osmotically active and stable b) They increase the stability of the entrapped drug
c) Biodegradable,non immunogenic and bio compatible d) All of the above
Ans: d
14. Organ Compartmentalization is following type of targeted delivery
a) First order targeting b) Second order targeting c) Third order targeting d) None
Ans: a
15. Identify the odd one from the following,
a) Liposome b) Reticuloendotyhelial system c) Microsphere and nanoparticles d) Monoclonal
antibodies
Ans: b
16. The body’s natural immune system is used in which type of targeting
a) Active b) Passive c) Physical d) Dual
Ans:b
17. Liposome, liquid particles and polymeric micelles belonging to which class of carrier
a) Soluble carrier b) cellular carrier c) particle carrier d) none of the above
Ans: c
18. Important characteristics of in-vivo environment is

a) Size b) Temperature c) Density d) Molecular weight

Ans: b
19. A monoclonal antibody(mAb or moAb) is an antibody made by cloning a unique__
a) RBC b) Calcium c) WBC d) serum
Ans: c
20. Liposome contains oil soluble material in ___ cavity.
a) polar b) hydrophilic c) neutral d) non polar
Ans: d
21. Liposome are spherical structure usually between _____ in diameter.
a) 80-100nm b) 60-100nm c) 55-100nm d) 15-1000nm
Ans: d
22. Liposomes were discovered by

a) Alec Bangham b) Handjani-vila c) George E.palade d) None of above

Ans: a

23. Controlling the rate of drug delivery to target site is called

a)Temporal Approach b) Spatial Approach c) Physical Approach d)None of the above

Ans: a

24. The analytical techniques used in the characterization of cholesterol auto oxidation and
anti oxidation degradation studies in Liposomes

a.) HPLC b) TLC c) GLC d) Both a&b

Ans: d

25. The approach in which the carrier molecule has therapeutic activity and thus increase
the therapeutic effect of drug is called

a) Dual targeting b) Passive targeting c) Double targeting d) None of the above

Ans: a

26. The following can be include in physicochemical characterisation of nanoparticles

a) Reverse dialysis b)surface properties c)crystality d)centrifugal ultrafiltration

Ans: c

27. Enhanced permeability and Retention is under which targeting approach

a) Active targeting b) Passive targeting c) Inverse targeting d) None of the above

Ans: b

28. Liposomes have -------- half-life

a) Longer b) Shorter c) Intermediate d) Both a & b

Ans: b

29. Nanomaterials differ significantly from other materials due to the following reason

a) Increased surface area b) Quantum effects C) Both a & b d) None of the

above

Ans : c

30. The main goal in designing nanoparticles as a delivery system

a)To control size and surface characteristics of particle

b)To achieve the site-specific action of the drug c)Both a) and b) d)None of the above

Ans : c

31. Chemical Characterization of Niosomes can be done by

a) Osmometer b) LAL test c) Electrophoresis d) Zeta potential

Ans: a

32. One of the following is the disadvantage of liposomes

a. Biologically inert b. Non antigenic c. Embolism d. Low elimination rate

Ans: c

33. Normal pH of the nasal secretion in adult is

a) 5.5-6.5 b) 3.5-4.5 c) 6.5-7.5 d) 2.5-3.5

Ans: a

34. Identify Monoclonal antibody associated with Alzheimer's Disease

a) Abciximab b) Alemtuzumab c) Aducanumab d) None of these.

Ans: c

35. The range of size of the colloidal particles used as nanoparticle is

a) 10-1000nm b) 1-100nm c) 100-10000nm d) All of the above

Ans: a

36. The normal function of Reticulo Endothelial system is suppressed in

a) Active targeting b) Passive targeting c) Inverse targeting d) Dual targeting

Ans: c

37. Non-ionic surfactant/s used to formulate niosomes

a. Tween-80 b. Cetrimide c. Alkyl sulphates d. All of the above

Ans: a

38. The terms FATMLV, SPLV, VET, DRV etc. are associated with

a. Niosomes b. Liposomes c. Ribosomes d. Nanoparticles

Ans: b

39. In nano-particulate drug delivery, drug may be released by

a. Desorption of surface bound drug b. Diffusion through the nanoparticle matrix

c. Matrix erosion d. All of the above

Ans: d

40. Liposomes can trap as

a) Hydrophobic compounds b)hydrophilic compounds c) both a & b d)none

Ans: c

41. Liposomes , lipid particles and polymeric mecellers belong to class of carrier
a. Soluble carriers b. cellular carriers c. Particle carriers d. None of above

Ans: c

42. Example of liposome-based drug available in the market

a. Cifran OD b.Lipodox c. Paracip d. Cytotec

Ans: b

43. Limitation of Nanoparticles

a.Particle-particle aggregation b.Handling of nanoparticles difficult in liquid and dry forms.

c.Limited drug loading d.All of the above

Ans: d

44. Identify Monoclonal antibody associated with Cancer treatment

a) Abciximab b) Alemtuzumab c) Aducanumab d) None of these.

Ans: b

45. The rate at which monolithic devices transfer drugs to the patient body is proportional to
_____of time.

a) Square of time b) The square root of time c) Twice the time d) Half the time

Ans: b

46.Targeted drug delivery system should not be

a. Biochemically inert b. chemically and physically stable in vivo and in vitro conditions

c. Biochemically toxic d. Non immunogenic

Ans: d

47. Choose one of the following is NOT true

a) Modified release formulations are most useful for drugs with a long half-life

b) Modified release formulations can often reduce side-effects

c) Modified release formulations can improve patient compliance

d) Modified release formulation can be used for local drug delivery

Ans: a
48. The following methods are used for the purification of nanoparticles

a) Dialysis b) gel filtration c) ultra centrifugation d) all of the above

Ans : d

BCDA COLLEGE OF PHARMACY & TECHNOLOGY

Hridaypur, Barasat, Kolkata – 700127

Multiple Choice Questions (MCQs)

Subject: B. Pharm

Course – Novel Drug delivery Systems

Code: PT - 716B

Year: 4th Sem: 7th

Session: 2020 – 2021 (odd)

GROUP I

13. Weight gain could be the major side effects of

a. First generation IUDs b. Second generation IUDs c. Third generation IUDs

d. All of the above

Ans: c

14. Menorrhagia is the side effect of Intra Uterine Devices in which there is

a. Prolonged bleeding b. Painful menstrural periods c. Shorter menstrural cycle d. None of the
above

Ans: a
15. Example of barrier method of contraception include?

a. Minipill b. Condom c. Progestasert d. All the above

Ans: b

16.Copper containing IUDs causes-

a. Lysosomal activation b. Lysosomal inactivation c. Fertilization d. None of the above

Ans: a

17. Non medicated IUD's have vanished from market because :

a. Menstrual bleeding b. Distance and lower patient compliance c. Pelvicinflammatory diseases

(PID) d. All of the above

Ans: d

18.Following is second generation intra uterine device?

a. Para gard b. Lippes loop c. Progestasert d. Mirena

Ans: a

19.In ocular drug delivery system SODI stands for

a. Soft Ocular Drug Inserts. b. Superoxide dismutase c. Soluble Opthalmic Drug Inserts. d.
Soluble Ocular Drug Implant.

Ans: c

20. The plasticizer used in ocular drug delivery system is -

a. HEC b. PEG c. PVP d. PAA

Ans: b

21. Most common disadvantage of ocular solution is -

a. rapid precorneal elimination b. non sustained action c. both a & b d. inconvience

Ans: c

22.The Levonorgestrel IUD/LNG IUD releases the hormone at an approximate rate of

a. 20 micrograms per day b. 20 micrograms per hour c. 200 micrograms per day d. 0.2
micrograms per day
Ans: a

23.Hormonal IUD contain

a. levonorgesteron b. Progesterone c. Estrogen d. all

Ans: d

GROUP II

24. First IUDs was developed in-

a) 1890 b) 1960 c) 1909 d) 1920
Ans:c

25. The benefits of hormonal IUDs include:

a) Highly effective b) More regular periods c) lower the risk of certain cancers d) all of the above
Ans:d

26.In ocular delivery system SODI stands for--

a) Soft ocular drug inserts b) Seperoxide dismutase c) Soluble ophthalmic drug inserts d)drug
implant
Ans:c

27.In intrauterine Drug delivery system LARC stands for-

a) Long acting Reservoir concentration b) Long acting Reversible contraception c) Light action
Reversible contraception d) Low acting Reversible contraception
Ans:b

28. Thick muscular middle layer made up of bundles of smooth muscle embedded
connective tissue is-
a) Peritoneum b) Myometrium c) Endometrium d) all of the above
Ans:b

29.Emergency prevention of pregnancy( < 6 days )most useful-

a) IUDs b) Regular pills (28 tab.) c) Prega kit (5 Tab.) d) Unwanted-72 (1 tab.)
Ans:b

30.The levonorgestrle IUD/LNG IUDs release the hormone at an approximate rate of-
a) 20microgram per hour b) 20microgram per day c) 200 microgram per day d) 0.2 microgram
per day
Ans:b

31.which is not example of ocular inserts device -

a) Ocuserts b) Gelfoam c) lipistic d) drops

Ans:c

32.The ophthalmic preparations are available as-

a) buffered b)sterile c) isotonic solution d) all of above.
Ans:d

33. Copper bearing IUDs example-

a)Tcu380A b)LNG-20 c) MLCu-375 d) a&c
Ans:d

34.To optimize good ocular drug delivery systems requires_

a) A good corneal penetration b) good rheological properties c) both a& b d) irritative form
Ans:c

GROUP III

35. Second generation IUDs are avoided for women with-

a) copper sensitivity. b) Wilson's disease. c) both a and b. d) none of the above.

Ans: c

36. Following is example of Hormonal Intra Uterine Device -

a) Mirena b)Liletta c)Progestasert d)All of the above

Ans: d

37. Second generation intra uterine device

a)para gard b)Lippes loop c)progestasert d)Mirena

Ans: a

38.Rate limiting barrier in third generation IUDS is of

a.Ethylene vinyl acetate copolymer b.Ethane vinyl acetate polymer c.Ethylene vinyl citrate
copolymer d.None of the above

Ans: a

39. Cupper ions are released from which type of IUDs

a. First Generation IUDs b. Second Generation IUDs c. Third Generation IUDs.

d. All of the above

Ans: b

40.The example of Barrier method of contraception includes

a. Minipill b. Condom c.progestasert d. All of the above

Ans: b.

41. Weight gain could be major side effect of--

a) First generation IUDs. b) Second generation IUDs. c) Third generation IUDs. d) All the
above.

Ans: c.

42.Menorrhagia is side effect of Intra Uterine Devices in which there is -

a) Prolonged bleeding b) Painful menstrual periods c) Shorter menstrual cycle

d) None of the above

Ans: a)

43. Discosomes are modified form of

a. Niosomes b.Liposome c. Ribosome d. None

Ans: a

44. Scleral drug delivery depends upon

a. Molecular size b. Ionic charge c. Particle size d. Both a&b

Ans: d

45. Non medicated intrauterine device is

a. Para gard b.lippes loop c. Progestasert d. Mirena

Ans. B

47. One of the following is a non-medicated IUD identify-

a) Progestasert b) Lippes Loop c) Mirena d) Liletta

Ans: b

48. Length of IUD------

a) 2.5cm b) 3.5cm c) 1.5cm d) 4cm

Ans: b

49. The copper IUD can cause ………

a) Allergic reaction b) Infection c) Bleeding d) all of the above

Ans : d

50. Followings are the first generation plastic intrauterine devices, except _____

a) Multiload IUDS b) Lippes loop c) Dalkon Shield d) All of the above

Ans: a

51. Cul-de-sac is the site of insertion for following occular drug delivery system-

a)Lacrisert b)SODI c)Minidisc d)AOT

Ans: d

52. Most common disadvantage of ocular solution is-

a) Rapid precorneal elimination b) Non sustained action

c) Both a & b d) Inconvenience

Ans: c

53. IUD can be left in the uterus for----

a) 3-5 years b) 2-4 years c) 2-5 years d) 3-6 years

Ans: c
54. The following statements are true about Intrauterine devices (IUD) except:

a) Multiload Cu-375 is a third generation IUD

b) The pregnancy rate of Lippes loop and Cu—T 200 are similar

c) IUD can be used for Emergency Contraception within 5 days

d) Levonorgestrel releasing IUD has an effective life of 5 years.

Ans: a

55. Second generation iuds are avoided for woman with -

a) Copper sensitivity b) Wilson's disease

c) Both d) None of the above

Ans: c

56. Copper ions are released from which type of IUDs-

a)First generation IUDs b)Second generation IUDs

c)Third generation IUDs d) All of the above

Ans: b

57. Metal Particle Test is carried out for evaluation of:

a. Eye ointment b. Eye suspension c. Both a&b d. Eye drops

Ans: a

GROUP IV

58. Copper T is effective for contraception due to

a. Progesterone b. Estradiol c. Oxytocin d. None of the above

Ans: d

59.which of the following conditions can be deliberated as category 4 for IUD placement according to
WHO?

a. Pregnancy b. Uterine infection c. Cervical cancer d. All of the above

Ans : d

60.Non medicated It's have vanished from market because

a. Menstrual bleeding b. Discomfort and lower patients compliance

c. Pelvic inflammatory diseases(PID) d. All of the above

Ans-d

61.The example of Barrier method of contraception includes-

a) Minipill

b) Condoms

c) Progestasert

d) all of thee above

Ans-b

64. The first IUD developed in the year-

a. 1890

b. 1909

c. 1920

d. 1960

Ans-b

65.Non medicated IUD's have vanished from market because-

a. Menstrual bleeding

b. Discomfort and lower patient complience

c. Pelvic inflammatory diseases

d. All of the above

Ans - d

66.Rate limiting barrier in third generation IUDS is of

a.Ethylene vinyl acetate copolymer

b.Ethane vinyl acetate polymer

c.Ethylene vinyl citrate copolymer

d.None of the above

Answer:a

67.Following formulations would not be applicable to ocular administration

a) Solution

b) Liniment

c) Suspension

d) Ointment

Ans: b

68.Discosomes are modified form of -

a)Niosome

b)Liposome

c)Ribosome

d) None of the above

Ans - a

GROUP V

17. Non medicated IUD's have vanished from market because :

a. Menstrual bleeding b. Distance and lower patient compliance c. Pelvicinflammatory diseases

(PID) d. All of the above
Ans: d

70. Ocular Therapeutic System (OTS) is also known as:

a. Lacrisert b. Minidisc c. SODI d. Ocusert

Ans: b

71. Most common disadvantage of ophthalmic ointments and gels is-

(a) Blurring of vision (b) Drug stability (c) Drug choice flexibility (d) All of the above

Ans: a

73. The plasticizer used in ocular drug delivery system is:

a. HEC b. PEG c. PVP d. PAA

Ans: b

74. In ocular drug delivery system SODI stands for :

a) Soft ocular drug inserts b) Superoxide dismutase c) Soluble ocular drug inserts d) Soluble
ocular drug implant

Ans – c

75. Most common disadvantage of Ocular solution is:

a. Rapid Precornial elimination b. Non sustained action c. Both a&b d. Inconvenience

Ans: c

77. The part of the eye is responsible for the function ‘Refracts Light Rays’:

a. Sclera b. Cornea c. Pupil d. Choroid

Ans: b

78. Objective of ocular drug delivery system is

a) increase bioavailability b) controlled release c) sustained release d) option a,b,c all

Ans : d

79. Copper containing IUDs causes..................

a) Lysosomal activation

b) Lysosomal inactivation

c) Fertilization

d) None of the other

Ans: a